Board of Directors
Our Board of Directors has breadth of experience in building companies and translating novel innovative technologies to meaningful products for patients. They have worked across a number of organizations and share our vision to bring transformational products to patients.
Helen S. Kim
Helen S. Kim, M.B.A., joined our board of directors in August 2018, bringing with her over 27 years of leadership experience in biotechnology. Ms. Kim currently serves as managing director of Vida Ventures, a position she has held since April 2019. From March 2018 to March 2019, Ms. Kim served as a partner at The Column Group. From June 2014 to January 2018, Ms. Kim served as executive vice president of Business Development at Kite Pharma, Inc. where she led all business and corporate development initiatives, including the successful buyout of Kite Pharma to Gilead in 2017. From August 2009 to November 2014, she served in various roles as strategic advisor and chief business officer at NGM Biopharmaceuticals, Inc. Prior to NGM, she was the chief executive officer and president of Kosan Biosciences where she restructured and repositioned the company prior to successfully selling the company to Bristol-Myers Squibb in 2008. She holds a B.S. in Chemical Engineering from Northwestern University and a M.B.A. from the University of Chicago. Ms. Kim also currently serves on the Board of Directors for Assembly Biosciences, A2 Biotherapeutics, Neogene, and Exicure, Inc.
Graham K. Cooper
Graham K. Cooper has served as a member of our board of directors since January 2020. From March 2018 until May 2019, Mr. Cooper served as the Chief Operating Officer and Chief Financial Officer of Assembly Biosciences, Inc. Mr. Cooper previously served as the Chief Financial Officer of Receptos, Inc., from February 2013 until its acquisition by Celgene in August 2015 and Chief Financial Officer of Geron Corporation from January 2012 to December 2012. From May 2006 until March 2011, Mr. Cooper served as Chief Financial Officer of Orexigen Therapeutics, Inc. Prior to that, Mr. Cooper held roles of increasing responsibility at Deutsche Bank Securities, an investment bank, from August 1997 to February 2006, including Director, Health Care Investment Banking. He began his career as an accountant at Deloitte & Touche, and was previously a C.P.A. Mr. Cooper currently serves on the boards of directors of Beam Therapeutics, Inc., Kezar Life Sciences, Inc., and Unity Biotechnology, Inc., all public biotechnology companies. Mr. Cooper received a B.A. in Economics from the University of California at Berkeley and an M.B.A. from the Stanford Graduate School of Business.
David A. Lamond joined our board of directors in September 2018. Since April 2016, Mr. Lamond has served as president of En Pointe LLC, an investment firm. From 2011 to 2016, he served as the president, chief executive officer and chief investment officer of Lamond Capital Partners LLC. Mr. Lamond also is currently a member of the board of directors of Cortexyme, a biopharmaceutical company, and previously served on the board of Arrinex, a medical device company. In addition, Mr. Lamond is on the board of directors of two non-profit organizations, Tipping Point Community and Ubuntu Pathways. Mr. Lamond holds a B.A. in History from Duke University and a J.D. from Duke Law School.
Tahir Mahmood, PhD
CEO & Co-Founder
Tahir co-founded AMT, where he has overseen the company’s growth from concept to clinical trials in patients through multiple equity financing rounds. He was closely involved in the early development of the technology and also led the company’s partnering and corporate development activities.
With a career that has straddled science and business, Tahir previously led the US West Coast Life Sciences consulting practice at Booz Allen Hamilton and was Managing Director at Lake Sherwood Partners. As a consultant, he advised executives across the spectrum of life sciences, healthcare provider, private and public equity investment, and global health organizations.
Tahir is also co-founder and director of MiNDERA, a non-invasive skin genomics company with a technology platform he co-invented and developed as an investigator at The Scripps Research Institute. He served as Principal Business Analyst at Amgen, supporting business development, M&A and strategic venture fund transactions. Earlier, he was at Chienna (acquired by OctoPlus) and IsoTis S.A. (acquired by Integra Life Sciences). Tahir has authored numerous peer-reviewed publications and is inventor on issued and pending patents. He received BASc and MSc degrees from the University of Toronto. He holds a PhD in Chemical & Biomedical Engineering from a collaborative program between the University of Twente (The Netherlands) and Massachusetts Institute of Technology at the Harvard-MIT Division of Health Sciences and Technology and Boston Children’s Hospital.
Randall Mrsny, PhD
CSO & Co-Founder
An epithelial biologist, Randy has more than three decades of industry and academic experience in pharmaceutical sciences and research into the mucosal trafficking of peptide and protein therapeutics.
He has overseen the development of AMT’s core molecular transport and targeting platforms and leads the company’s Platform Strategies Group that is advancing tools and applications for the underlying technology. Previously, he led research groups at Genentech (Drug Delivery/Biology) and ALZA (Peptide Biology), and holds an academic position at the University of Bath (UK), where he took the Professor’s Chair of Epithelial Cell Biology.
Randy has served as an advisor to governments and multinational agencies and is the recipient of many awards and commendations, including being elected as President and to the College of Fellows of the Controlled Release Society (CRS) and in 2019 was awarded the Founders Award by the CRS for his contributions to the field.
Randy obtained a BS in Biochemistry and Biophysics at the University of California at Davis, a PhD in Anatomy and Cell Biology at the U.C. Davis School of Medicine, and was a NIH Postdoctoral Fellow in Membrane Biophysics in the Institute of Molecular Biology at the University of Oregon.
Aaron VanDevender, PhD
Dr. VanDevender joined our board of directors in November 2016. Since February 2020, Dr. VanDevender has served as Chief Scientific Consultant at Founders Fund, LLC, a venture capital firm and from November 2012 to February 2020, Dr. VanDevender served as Chief Scientist and Principal at Founders Fund, LLC. From October 2010 to March 2012, Dr. VanDevender served as a physicist at Halcyon Molecular, Inc., a company focused on DNA sequencing technology. From October 2007 to September 2010, he worked as a physicist at the National Institute of Standards and Technology. Dr. VanDevender holds a BS in Physics from the Massachusetts Institute of Technology and a PhD in Physics from the University of Illinois, Urbana-Champaign.